State Street’s Context Therapeutics CNTX Stock Holding History

State Street’s Portfolio CNTX Stock Details CNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$437K	Buy	1,455,898 +42,470	+3%	+$21K	﹤0.01%	3694
2026 Q2	$783K	Buy	1,413,428 +1,179,921	+505%	+$2.39M	﹤0.01%	3565
2026 Q1	$612K	Buy	233,507 +67,900	+41%	+$159K	﹤0.01%	3606
2025 Q4	$243K	Buy	165,607 +13,000	+9%	+$15.2K	﹤0.01%	3856
2025 Q3	$148K	Hold	152,607	–	–	﹤0.01%	3979
2025 Q2	$100K	Hold	152,607	–	–	﹤0.01%	3973
2025 Q1	$93.4K	Hold	152,607	–	–	﹤0.01%	3985
2024 Q4	$160K	Buy	152,607 +40,700	+36%	+$70.4K	﹤0.01%	3897
2024 Q3	$219K	Buy	111,907 +19,800	+21%	+$43.9K	﹤0.01%	3804
2024 Q2	$185K	Buy	92,107 +59,200	+180%	+$102K	﹤0.01%	3847
2024 Q1	$45.4K	Hold	32,907	–	–	﹤0.01%	4179
2023 Q4	$37.2K	Hold	32,907	–	–	﹤0.01%	4253
2023 Q3	$49.7K	Hold	32,907	–	–	﹤0.01%	4291
2023 Q2	$52.7K	Hold	32,907	–	–	﹤0.01%	4406
2023 Q1	$18.5K	Hold	32,907	–	–	﹤0.01%	4690
2022 Q4	$21.7K	Hold	32,907	–	–	﹤0.01%	4720
2022 Q3	$37K	Buy	32,907 +14,607	+80%	+$26.3K	﹤0.01%	4717
2022 Q2	$39K	Buy	+18,300	New	+$34.3K	﹤0.01%	4769

Other funds holding CNTX

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Landscape Capital Management Englewood, New Jersey $1.34B AUM 18.69% 1-Year Est. Return

TGY2IT

Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

State Street's CNTX Position: Q3 2026 in Review

State Street increased its Context Therapeutics (CNTX) stake by 3% in Q3 2026, buying an estimated $21K and bringing the position to 1,455,898 shares worth $437K. The position accounts for ﹤0.01% of the portfolio, ranked #3694.

State Street first reported a position in CNTX in Q2 2022 and has held it in 18 quarters since. The position peaked at $783K in Q2 2026. 47 funds tracked by Wall St. Rank hold CNTX as of Q3 2026.

State Street held 1,455,898 shares of Context Therapeutics worth $437K as of Q3 2026.
State Street bought 42,470 Context Therapeutics shares in Q3 2026, an estimated $21K.
Context Therapeutics made up ﹤0.01% of State Street's portfolio in Q3 2026, its #3694 holding.
State Street first reported a position in Context Therapeutics in Q2 2022 and has held it in 18 quarters since.
State Street's Context Therapeutics position peaked at $783K in Q2 2026.
47 funds tracked by Wall St. Rank held Context Therapeutics as of Q3 2026.

Based on State Street's 13F filing for Q3 2026, filed 12 Nov 2026.